Health-related quality of life with neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin ineligible: phase 3 KEYNOTE-905 study.

Peter H. O'Donnell, MD

May 30, 2026, 8:00AM CDT

Abstract & Presentation

Abstract & Presentation

The content displayed at the congress

These materials are for personal use only and not for reproduction.